Skip to content

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$158.92B-2.6%
Eli Lilly logo
Eli LillyLLY
$859.77B+10.6%
Pfizer logo
PfizerPFE
$222.4B+9.2%
Merck & Co. logo
Merck & Co.MRK
$341.11B+34.2%
Amgen logo
AmgenAMGN
$246.43B+9.9%
Royalty Pharma logo
Royalty PharmaRPRX
$28.94B+44.6%

Other financials

Income statement

See full
Revenue-
Operating income-$445.2M-84.9%
Net income-$453.8M-113%
EPS (diluted)-$2.29-103%

Balance sheet

See full
Cash & equivalents$440.9M+32.2%
Total debt$156.6M+16.6%
Total equity$1.5B-27.8%
Total assets$2.3B-4.7%

Cash flow

See full
Operating cash flow-$354.2M-82.2%
CapEx$1.5M-52.9%
Free cash flow-$355.7M-79.9%

Valuation

See full
Market cap$33.54B+193%

Profitability

See full
Operating margin-88,031.9%-89,488pp
Net margin-76,423.3%-77,733pp

Returns & leverage

See full
Return on equity-76.7%-923pp
Debt / equity0.1×0.0×
Current ratio6.8×-6.7×

Where this comes from

Calculated from Revolution Medicines, Inc.’s reported figures.

The official record: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revolution Medicines, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Revolution Medicines, Inc.'s enterprise value?
Revolution Medicines, Inc. (RVMD) reported enterprise value of $18.99B in Q1 2026.
How has Revolution Medicines, Inc.'s enterprise value changed year-over-year?
Revolution Medicines, Inc.'s enterprise value increased by 197.9% year-over-year, from $6.37B to $18.99B.
What is the long-term trend for Revolution Medicines, Inc.'s enterprise value?
Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s enterprise value has grown at a 42.9% compound annual growth rate (CAGR), from $8.98B to $37.41B.
What does enterprise value mean?
What it would cost to buy the entire business, debt included and cash netted out.
How do you interpret enterprise value?
The capital-structure-neutral valuation base — used in EV/EBITDA and EV/Sales to compare companies with different leverage on a like-for-like footing.
How does enterprise value compare across companies?
Comparable across non-financial companies via the EV multiples it feeds; not used for banks and insurers.